Search All UT System Experts

Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

J. Spicer, R. Baird, A. Suder, N. Cresti, J. Garcia Corbacho, L. Hogarth, E. Frenkel, S. Matsumoto, I. Kawabata, K. Donaldson, J. Posner, D. Sarker, D. Jodrell, R. Plummer

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours'. Together they form a unique fingerprint.

Medicine & Life Sciences